Business & Finance
Jazz Pharmaceuticals reports 2018 financial results
27 February 2019 -

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, announced yesterday it financial results for 2018.

The company reported GAAP net income for 2018 at USD447.1m, or USD7.30 per diluted share, compared to USD487.8m or USD7.96 per diluted share in 2017.

The firm posted adjusted net income for 2018 at USD838.6m, compared to USD676.7m in 2017.